Biopharmx Corp (BPMX) Major Shareholder Vivo Capital Viii, Llc Sells 296,394 Shares
Biopharmx Corp (NYSE:BPMX) major shareholder Vivo Capital Viii, Llc sold 296,394 shares of the stock in a transaction that occurred on Thursday, November 9th. The stock was sold at an average price of $0.20, for a total transaction of $59,278.80. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Major shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.
Biopharmx Corp (NYSE BPMX) traded up $0.01 during midday trading on Monday, reaching $0.19. The company’s stock had a trading volume of 1,067,336 shares, compared to its average volume of 1,620,000. Biopharmx Corp has a 52-week low of $0.16 and a 52-week high of $0.90.
Biopharmx Corp (NYSE:BPMX) last released its quarterly earnings results on Wednesday, September 13th. The biotechnology company reported ($0.06) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.06). The firm had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.02 million. Biopharmx Corp had a negative return on equity of 5,749.08% and a negative net margin of 22,005.88%.
A number of analysts recently issued reports on the stock. Maxim Group reissued a “buy” rating and set a $1.50 target price (down previously from $3.00) on shares of Biopharmx Corp in a research report on Wednesday, September 13th. HC Wainwright reissued a “buy” rating and set a $3.00 target price on shares of Biopharmx Corp in a research report on Tuesday, September 19th.
Biopharmx Corp Company Profile
BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia.
Receive News & Ratings for Biopharmx Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx Corp and related companies with MarketBeat.com's FREE daily email newsletter.